Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymosin Alpha-1 for Immune-Related Adverse Events
NCT06178146Phase 4Recruiting
- Start
- Sep 2023
- Primary completion
- Nov 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of thymosin alpha 1 in immune-related adverse events (irAEs). Started Sep 2023; status: recruiting.
02
Drugs
thymosin alpha 1
03
Conditions
immune-related adverse events (irAEs)
Beyond the preview
Go deeper on NCT06178146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06178146.